Scholarlink

<p>This study aims to explore the therapeutic efficacy of evidence-based pharmaceutical interventions in pharmacist-integrated clinic for pediatric Mycoplasma pneumoniae pneumonia.</p><p>A total of 200 children with suspected Mycoplasma pneumoniae pneumonia admitted to our hospital between July 2022 and June 2024 were enrolled and randomly assigned to either the intervention group or the control group using a random number method. The intervention group received standardized diagnostic and therapeutic procedures based on evidence-based medicine principles, while the control group received conventional treatment according to the doctor’s standard practices. The two groups were compared regarding basic clinical parameters including time to defervescence, recovery duration, and medication use. Additionally, children treated with doxycycline underwent one-year dental follow-up.</p><p>The intervention group demonstrated significantly better outcomes compared to controls across all measured parameters: time to defervescence (3.37±1.24 vs 4.77±1.21 d), recovery duration (9.37±4.26 vs 12.51±5.12 d), total treatment costs (¥769±452 vs ¥2988±1899), and&#xa0;medication course length (10.68±3.02 vs 14.88±4.36 d). Additionally, the intervention group showed lower hospitalization cases (8 vs 65), intravenous infusion cases (8 vs 65), and adverse drug reactions (7 vs 18). Notably, no cases of tooth yellowing were observed during the 12-month follow-up period in children who received doxycycline treatment.</p><p>The evidence-based intervention via a pharmacist-integrated clinic significantly improved diagnostic accuracy and therapeutic efficacy for pediatric Mycoplasma pneumoniae pneumonia, with concomitant treatment costs reduction. No cases of doxycycline-induced tooth discoloration were observed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic efficacy of pharmacist-integrated clinic in evidence-based treatment for pediatric mycoplasma pneumoniae pneumonia

  • 期刊论文

  • 发表日期：

    2025年11月13日

查看全文
  • Zecheng Huang,
  • Xin Mei,
  • Mei Bai,
  • Pin Xiao,
  • Yuan Tao

摘要

This study aims to explore the therapeutic efficacy of evidence-based pharmaceutical interventions in pharmacist-integrated clinic for pediatric Mycoplasma pneumoniae pneumonia.

A total of 200 children with suspected Mycoplasma pneumoniae pneumonia admitted to our hospital between July 2022 and June 2024 were enrolled and randomly assigned to either the intervention group or the control group using a random number method. The intervention group received standardized diagnostic and therapeutic procedures based on evidence-based medicine principles, while the control group received conventional treatment according to the doctor’s standard practices. The two groups were compared regarding basic clinical parameters including time to defervescence, recovery duration, and medication use. Additionally, children treated with doxycycline underwent one-year dental follow-up.

The intervention group demonstrated significantly better outcomes compared to controls across all measured parameters: time to defervescence (3.37±1.24 vs 4.77±1.21 d), recovery duration (9.37±4.26 vs 12.51±5.12 d), total treatment costs (¥769±452 vs ¥2988±1899), and medication course length (10.68±3.02 vs 14.88±4.36 d). Additionally, the intervention group showed lower hospitalization cases (8 vs 65), intravenous infusion cases (8 vs 65), and adverse drug reactions (7 vs 18). Notably, no cases of tooth yellowing were observed during the 12-month follow-up period in children who received doxycycline treatment.

The evidence-based intervention via a pharmacist-integrated clinic significantly improved diagnostic accuracy and therapeutic efficacy for pediatric Mycoplasma pneumoniae pneumonia, with concomitant treatment costs reduction. No cases of doxycycline-induced tooth discoloration were observed.